Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis

Stock Information for Exicure Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Exicure Inc.

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors
Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update
Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.